… ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration … directed to up to five targets u sing ProQR’s proprietary Axiomer ® RNA editing platform ProQR to receive $ 5 0 million …
… ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio LEIDEN, Netherlands & CAMBRIDGE, Mass., … a key patent for its ADAR-mediated RNA editing platform Axiomer™. The opposition was filed in June 2021 with the …
… ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration Partnership focused on … said Daniel A. de Boer, Chief Executive Officer of ProQR. “Axiomer has the potential to restore precise levels of the …
… ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 LEIDEN, … transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today announced a …
… ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 Platform … transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted …
… ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event Initial … during which the Company will showcase its proprietary Axiomer RNA-editing technology platform, detail the pipeline, …
… ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and … and Clinical Date: November 18, 2022 at 2:30pm CET About Axiomer ® Technology ProQR is pioneering a next-generation …
… ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and … and Clinical Date: May 11, 2022 at 11:15am EDT About Axiomer ® Technology ProQR is pioneering a next-generation …
… ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing LEIDEN, … a key patent for its ADAR-mediated RNA editing platform Axiomer®. The oppositions were filed in February 2021 with …
